Enasidenib

AML: new targeted inhibitors as single agents? 1:42
AML: new targeted inhibitors as single agents?
Christoph Röllig
Enasidenib for IDH2-mutated MDS 1:13
Enasidenib for IDH2-mutated MDS
Valeria Santini
Progress in AML & research at the University of Düsseldorf 1:27
Progress in AML & research at the University of Düsseldorf
Thomas Schröder
Personalized AML therapy with John Byrd: the beat AML trial and more 4:31
Personalized AML therapy with John Byrd: the beat AML trial and more
John Byrd
Ivosidenib or enasidenib with chemotherapy for AML produces deep remissions 2:52
Ivosidenib or enasidenib with chemotherapy for AML produces deep remissions
Eytan Stein
Beat AML: promising results with enasidenib for AML in the frontline 2:25
Beat AML: promising results with enasidenib for AML in the frontline
Eytan Stein
IDH inhibitors for AML: highlights from ASH 2018 1:25
IDH inhibitors for AML: highlights from ASH 2018
Marina Konopleva
IDH1/2 inhibitors for upfront AML therapy and transfusion independence 1:51
IDH1/2 inhibitors for upfront AML therapy and transfusion independence
Amir Fathi
Gene-based treatments show positive outcomes in AML 4:42
Gene-based treatments show positive outcomes in AML
Harry Erba
Gene-targeting therapies for AML 4:06
Gene-targeting therapies for AML
Harry Erba
The promising role of IDH inhibitors in AML 1:53
The promising role of IDH inhibitors in AML
Amir Fathi
Novel drugs and targets in MDS 3:29
Novel drugs and targets in MDS
Valeria Santini
A success story: IDH inhibitors for AML 2:13
A success story: IDH inhibitors for AML
Alexander Perl
Changes in the AML treatment landscape 3:51
Changes in the AML treatment landscape
Richard Stone
Future therapies for AML: bispecifics and small molecule inhibitors 4:14
Future therapies for AML: bispecifics and small molecule inhibitors
Farhad Ravandi
IDH inhibitors for AML and MDS 1:32
IDH inhibitors for AML and MDS
Eunice Wang
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals